ISSN: 2474-9214
Authors: Ana Isabel FS, Carballido AF and Ana Isabel TS*
The development of nanomedicines decorated with ligands specifically recognized by cancer cells is a promising strategy to get a selective location of the antitumor drug at tumor cells, increasing its efficacy and reducing adverse effects. One of the most interesting ligands is folic acid, whose α-type-receptors are over expressed in numerous kinds of carcinomas. Several folic acid nanomedicines such as nanoparticles, micelles and liposomes have shown to increase the efficacy of conventional anticancer drugs in gynecological carcinomas, becoming in engaging therapeutics tools in these malignances.
Keywords: Folic acid; Nanomedicine; Tumor targeting; ovarian cancer; Breast cancer; Cervix cancer
